Результаты исследований: Научные публикации в периодических изданиях › обзорная статья › Рецензирование
Inhibitors of DNA glycosylases as prospective drugs. / Mechetin, Grigory V.; Endutkin, Anton V.; Diatlova, Evgeniia A. и др.
в: International Journal of Molecular Sciences, Том 21, № 9, 3118, 28.04.2020.Результаты исследований: Научные публикации в периодических изданиях › обзорная статья › Рецензирование
}
TY - JOUR
T1 - Inhibitors of DNA glycosylases as prospective drugs
AU - Mechetin, Grigory V.
AU - Endutkin, Anton V.
AU - Diatlova, Evgeniia A.
AU - Zharkov, Dmitry O.
N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/4/28
Y1 - 2020/4/28
N2 - DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.
AB - DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.
KW - DNA glycosylases
KW - DNA repair
KW - Drug targets
KW - ESCHERICHIA-COLI FPG
KW - BASE-EXCISION-REPAIR
KW - drug targets
KW - PROINFLAMMATORY GENE-EXPRESSION
KW - VACCINIA VIRUS
KW - SENSITIVE DETECTION
KW - PROCESSIVITY FACTOR
KW - SMALL-MOLECULE INHIBITOR
KW - SIGNAL AMPLIFICATION
KW - SUBSTRATE-SPECIFICITY
KW - PSEUDOMONAS-AERUGINOSA
UR - http://www.scopus.com/inward/record.url?scp=85083977621&partnerID=8YFLogxK
U2 - 10.3390/ijms21093118
DO - 10.3390/ijms21093118
M3 - Review article
C2 - 32354123
AN - SCOPUS:85083977621
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 9
M1 - 3118
ER -
ID: 24159462